Kura Oncology (KURA) Income from Non-Controlling Interests (2015 - 2026)
Kura Oncology's (KURA) quarterly Income from Non-Controlling Interests came in at -$1.4 million in Q1 2026, down 768.57% year-on-year from $210000.0 in Q1 2025, and down 778.26% on a QoQ basis from $207000.0 in Q3 2025.
Kura Oncology (KURA) Income from Non-Controlling Interests (2015 - 2026) Analysis & Trends
Kura Oncology (KURA) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$1.4 million in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 768.57% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 158.47% decrease from a year earlier, with the FY2015 full-year figure at -$87000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$1.4 million, down from $207000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for KURA reached as high as $1.6 million in Q3 2024 and fell as low as -$1.4 million in Q1 2026.
- Historically, Income from Non-Controlling Interests has averaged $113666.7 across 3 years, with a median of $208500.0 in 2025.
- Across the five-year window, Income from Non-Controlling Interests tumbled 86.89% in 2025 and plunged 768.57% in 2026, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $1.6 million in 2024, then tumbled by 86.89% to $207000.0 in 2025, then slumped by 778.26% to -$1.4 million in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$1.4 million in Q1 2026, $207000.0 in Q3 2025, and -$263000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Kura Oncology | 916.67 Mn | 916.67 Mn | 18.00 Mn | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Mar 31, 2025 | 210,000.00 |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 353,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Mar 31, 2020 | 230,000.00 |
| Dec 31, 2019 | -463,000.00 |
| Sep 30, 2019 | 171,000.00 |
| Jun 30, 2019 | 143,000.00 |
| Mar 31, 2019 | 149,000.00 |
| Dec 31, 2018 | 74,000.00 |
| Sep 30, 2018 | -30,000.00 |
| Jun 30, 2018 | -25,000.00 |
| Mar 31, 2018 | -19,000.00 |
| Dec 31, 2017 | -4,000.00 |
| Sep 30, 2017 | 8,000.00 |
| Jun 30, 2017 | -3,000.00 |
| Mar 31, 2017 | -1,000.00 |